Use of Intravenous Acetaminophen in Pediatrics Undergoing Spinal Fusion Surgery

Sponsor
Asan Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04959591
Collaborator
(none)
102
1
3
12.2
8.4

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate whether perioperative intravenous acetaminophen administration reduces postoperative pain and opioid consumption in adolescents and pediatric patients undergoing spinal fusion surgery.

Condition or Disease Intervention/Treatment Phase
  • Drug: intravenous acetaminophen
  • Drug: intravenous acetaminophen
  • Drug: Placebo
Phase 3

Detailed Description

Spinal fusion surgery to correct scoliosis causes severe postoperative pain in adolescents and pediatric patients. Thus, appropriate control of postoperative pain has a significant impact on postoperative recovery, patient satisfaction and reduction of hospital stay. Although pain control was achieved through only opioids, the importance of multimodal analgesia has recently been emphasized as opioid addiction and side effects increase.

Acetaminophen is recommended as a key factor in multimodal analgesia and previous studies performed in adult spine surgery showed that intravenous administration of acetaminophen reduced the postoperative pain and opioid consumption. In addition, acetaminophen is a drug widely recognized for safety in adolescents and pediatric patients and has a fast and predictable analgesic effect. Therefore, the purpose of this study is to investigate whether perioperative intravenous acetaminophen administration reduces postoperative pain and opioid consumption in adolescents and pediatric patients undergoing spinal fusion surgery. Thus the specific aim of this trial the investigators will determine is;

  1. The decrease in postoperative analgesic requirement following IV acetaminophen

  2. The decrease in intensity of postoperative pain following IV acetaminophen

  3. The quality of recovery including self-reported recovery, physical and functional recovery and length of stay

  4. The preemptive analgesic effect of IV acetaminophen

Study Design

Study Type:
Interventional
Anticipated Enrollment :
102 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
The designated research pharmacist will prepare the both study drug (IV acetaminophen) and placebo and will dispense the study drug according to treatment allocation. Treatment allocation will remain concealed from all other investigators involved in the conduct and analysis of the trial. All other medical staff involved in patient care during the hospital stay of study participant and the study participants itself along with guardians will be also blinded throughout.
Primary Purpose:
Treatment
Official Title:
Use of Intravenous Acetaminophen in Adolescents and Pediatrics Undergoing Spinal Fusion Surgery: Randomized Controlled Trial
Actual Study Start Date :
Jun 1, 2021
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 7, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental (Pre): Acetaminophen

Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg after anesthetic induction/before surgical incision and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given at the end of surgery before skin closure.

Drug: intravenous acetaminophen
experimental(pre): administration of IV acetaminophen

Experimental: Experimental(post): Acetaminophen

Participants will receive 15mg/kg intravenous acetaminophen 15mg/kg at the end of surgery before skin closure and the same dose will be given postoperatively at 8 hour intervals for 24hours. A single dose of placebo (saline) will also be given after anesthetic induction/before surgical incision.

Drug: intravenous acetaminophen
experimental(post): administration of IV acetaminophen

Placebo Comparator: Placebo comparator : placebo

Participants will receive 1.5ml/kg placebo (0.9% saline) before and after surgery and the same dose will be given postoperatively at 8hour intervals for 24hours.

Drug: Placebo
placebo comparator: administration of normal saline

Outcome Measures

Primary Outcome Measures

  1. Postoperative analgesic consumption [24 hours after surgery]

    Comparison of total analgesic consumption between 3 groups in morphine equivalent

Secondary Outcome Measures

  1. Postoperative analgesic consumption [48 hours after surgery]

    Comparison of total analgesic consumption between 3 groups in morphine equivalent

  2. Post operative pain scores [4, 8, 24, 48 hours after surgery]

    Comparison of NRS(numerical rating scale: 0, no pain, 10, worst possible pain) between 3 groups: Worst (cough) and mean pain scores

  3. Frequency of side effects of opioids [24, 48, 72 hours after surgery]

    respiratory depression, postoperative nausea/vomiting, itching, constipation

  4. Quality of recovery questionaire [3 to 5 days after surgery]

    self reported Quality of recovery-15 (QoR-15: 0, very poor recovery, 150, excellent recovery) questionnaire

  5. Postoperative recovery [from end of surgery to discharge from hospitalization (average 7 days)]

    Timing of oral intake(hr), timing of ambulation(hr)

  6. Length of hospital day [from end of surgery to discharge from hospitalization (average 7 days)]

    postoperative hospital stay(days), intensive care unit admission(days)

Eligibility Criteria

Criteria

Ages Eligible for Study:
11 Years to 20 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • American Society of Anesthesiologists (ASA) physical status 1-3

  • patients undergoing spinal fusion surgery

Exclusion Criteria:
  • patients who refuse to participate in this study

  • patients unable to communicate due to mental impairment or developmental delay

  • patients allergic to acetaminophen or its additives or who are contraindicated in acetaminophen administration for other reasons

  • patients with existing liver diseases or dysfunction (i.e. active hepatitis, clinically relevant chronic liver conditions, elevated liver enzymes)

  • patients who are judged ineligible by the medical staff to participate in the study for other reasons

Contacts and Locations

Locations

Site City State Country Postal Code
1 Asan Medical Center Seoul Korea, Republic of 05505

Sponsors and Collaborators

  • Asan Medical Center

Investigators

  • Principal Investigator: Won Uk Koh, M.D, Ph.D, Asan Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Won Uk, Koh, Associate professor, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT04959591
Other Study ID Numbers:
  • 2021-0411
First Posted:
Jul 13, 2021
Last Update Posted:
Jul 20, 2021
Last Verified:
Jul 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Won Uk, Koh, Associate professor, Asan Medical Center
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 20, 2021